# iCAT for Recurrent/Refractory/HR Solid Tumors

> **NCT01853345** · — · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 101 (actual)

## Conditions studied

- Pediatric Solid Tumor
- Sarcoma
- Neuroblastoma
- Wilms Tumor

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01853345
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-09
- **Final completion:** —
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853345, "iCAT for Recurrent/Refractory/HR Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01853345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*